Fluoxetine bridging for difficult antidepressant tapering
Medically reviewed by: Ruben de Groot, doctor Last reviewed:
For some people, tapering an antidepressant using standard tablet strengths is difficult. The final dose reductions can sometimes produce disproportionately large changes. In selected situations, a clinician may therefore consider temporary substitution with fluoxetine as a tapering bridge.
What makes fluoxetine different?
Fluoxetine is an SSRI, but it has an unusually long duration of action.
Fluoxetine itself remains in the body for a relatively long time. It is also converted into norfluoxetine, an active metabolite with an even longer elimination half-life.
As a result, serotonergic exposure declines much more gradually after dose reduction or discontinuation than it does with many other antidepressants.
This differs substantially from shorter-acting antidepressants such as paroxetine or venlafaxine.
Why can a long half-life help?
The relationship between antidepressant dose and pharmacological effect is not simply linear.
At the lower end of the dose range, a seemingly small reduction in milligrams may therefore result in a relatively larger change in serotonin-transporter occupancy.
A long-acting medicine such as fluoxetine also produces a natural taper after the final dose, as fluoxetine and norfluoxetine leave the body gradually over an extended period.
In selected cases, this can provide a pharmacokinetic buffer.
Read more about hyperbolic tapering.
When may fluoxetine bridging be considered?
A fluoxetine bridge may be considered when, for example:
- previous tapering attempts caused significant withdrawal symptoms;
- the smallest standard tablet strength still represents too large a final reduction;
- very small daily doses are difficult to implement reliably;
- liquid preparations, bead counting or compounded medication would be difficult to use;
- the original antidepressant is a serotonergic drug for which fluoxetine substitution is pharmacologically appropriate.
A bridge is not automatically required whenever someone wishes to stop an antidepressant. Many people can taper their original antidepressant directly.
What does the literature describe?
In 2025, Shapiro and Cohrs published a technical protocol for fluoxetine substitution when tapering serotonin reuptake inhibitors that have proved difficult to discontinue.
Their approach can broadly be divided into four stages.
Reduce the original antidepressant first
The original serotonergic antidepressant is initially reduced as far as practical using conventionally available doses.
Introduce low-dose fluoxetine
If further tapering remains difficult, the authors describe a temporary period of low-dose fluoxetine co-treatment.
The aim is to allow enough time for fluoxetine and norfluoxetine to accumulate before the original antidepressant is completely removed.
Discontinue the original antidepressant
Once stable, the original drug is reduced further and ultimately discontinued.
Allow fluoxetine itself to taper out
Fluoxetine is subsequently reduced gradually as well. Because of the long half-lives of fluoxetine and norfluoxetine, intermittent dosing may be used in selected situations.
If clinically significant withdrawal still occurs, the authors describe either using a still lower dose or less frequent dosing as possible individual adaptations.
This protocol is a pharmacologically and clinically reasoned proposal. Controlled trials have not yet established that fluoxetine substitution is superior to a well-conducted conventional or hyperbolic taper.
Not all antidepressants are the same
Fluoxetine bridging primarily addresses the serotonergic component of withdrawal.
It is therefore not equally suitable for every antidepressant.
Some drugs have clinically relevant effects on other pharmacological systems. An SSRI bridge may not fully compensate for withdrawal related to noradrenergic, anticholinergic or antihistaminergic effects.
Suitability must therefore be assessed for the individual medication.
Read more about tapering antidepressants.
Drug interactions matter
Fluoxetine is a strong inhibitor of CYP2D6.
It can therefore alter concentrations or effects of other medicines. This may be relevant to certain beta blockers, opioids, psychotropic drugs and tamoxifen, among others.
Temporary co-treatment with another serotonergic antidepressant also requires a deliberate clinical assessment.
A fluoxetine bridge should therefore begin with a medication and interaction review.
Withdrawal or recurrence?
Symptoms during tapering may include:
- dizziness;
- restlessness;
- sleep disturbance;
- emotional lability;
- nausea;
- sweating;
- fatigue;
- sensory symptoms such as electric-shock sensations.
The timing and pattern of symptoms can help distinguish withdrawal from recurrence of the original depressive or anxiety disorder.
The distinction is not always immediately clear.
Read more about antidepressant withdrawal.
Our approach
At Medicatie Afbouwpoli, fluoxetine is not used as a universal solution.
We first assess:
- which antidepressant is being used;
- current and previous doses;
- previous tapering attempts;
- symptoms occurring during dose reductions;
- other medication and potential interactions;
- simpler tapering options already available.
Our principle is: as simple as possible, as gradual as necessary.
For some people, standard tablet strengths are sufficient. Others may benefit from a slower or more hyperbolic taper. In selected cases, fluoxetine bridging may provide a practical alternative.
Sources
- NICE. Depression in adults: treatment and management (NG222) — recommendations on stopping antidepressants.
- Shapiro B, Cohrs D. Fluoxetine substitution for deprescribing antidepressants: a technical approach. Journal of Psychiatry & Neuroscience. 2025;50(4)–E209.
- Dutch multidisciplinary guidance on tapering SSRIs and SNRIs — NHG, KNMP, NVvP and MIND.
Further reading
This page provides general medical information and is not an individual tapering prescription.